5/23/2023

Methylprednisolone Sodium Succinate Injection

Products Affected - Description

- Solu-Medrol injection, Pfizer, 1 gram, single dose vial, 1 count, NDC 00009-0698-01
- Solu-Medrol injection, Pfizer, 1 gram, Act-O-Vial single dose vial, 1 count, NDC 00009-0018-20
- Solu-Medrol injection, Pfizer, 125 mg, Act-O-Vial single dose vial, 25 count, NDC 00009-0047-22
- Solu-Medrol injection, Pfizer, 2 gram, single dose vial, 1 count, NDC 00009-0850-01
- Solu-Medrol injection, Pfizer, 40 mg, Act-O-Vial single dose vial, 25 count, NDC 00009-0039-28
- Solu-Medrol injection, Pfizer, 500 mg, single dose vial, 1 count, NDC 00009-0758-01
- Solu-Medrol injection, Pfizer, 500 mg, Act-O-Vial single dose vial, 1 count, NDC 00009-0003-02
- Methylprednisolone Sodium Succinate powder for solution for injection, Fresenius Kabi, 1 gram, single dose vial, 1 count, NDC 63323-0265-30
- Methylprednisolone Sodium Succinate powder for solution for injection, Fresenius Kabi, 125 mg, single dose vial, 25 count, NDC 63323-0258-03
- Methylprednisolone Sodium Succinate powder for solution for injection, Fresenius Kabi, 40 mg, single dose vial, 25 count, NDC 63323-0255-03

Reason for the Shortage

- Pfizer has Solu-Medrol on shortage due to manufacturing delays.
- Fresenius Kabi did not provide a reason for the shortage.

Available Products

- There is insufficient supply for usual ordering

Estimated Resupply Dates

- Fresenius Kabi has methylprednisolone sodium succinate 40 mg, 125 mg, and 1 gram vials on back order and the company estimates a release date of early-June 2023 for the 40 mg vials and mid-June 2023 for the 125 mg vials and 1 gram vials.
- Pfizer has Solu-Medrol 40 mg Act-O-Vials, 125 mg Act-O-Vials, 500 mg vials, 500 mg Act-O-Vials, 1 gram vials, 1 gram Act-O-Vials, and 2 gram vials available in limited supply.

Updated

Updated May 23, 2023 by Michelle Wheeler, PharmD, Drug Information Specialist. Created March 23, 2023 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2023, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.